analysis of statistics

Incyte Corporation (NASDAQ:INCY)’s share price soared 1.93% or 1.42 to reach at $75.12 during previous trading session. A total of 1.84 Million shares exchanged hands, whereas the company’s average trading volume stands at 1.72 Million shares. Incyte Corporation (NASDAQ:INCY) has a market capitalization of $15.97 Billion and most recently 212.63 Million outstanding shares have been calculated.

According to sentiments of 15 analysts the mean estimates of short term price target for the company’s stock is marked at $83.67. The most optimistic analyst sees the stock reaching $102 while the most conventional predicts the target price at $70.

In terms of Buy/Sell recommendations, 18 analysts have a consensus rating of 1.83 on the shares of Incyte Corporation (NASDAQ:INCY). Out of rating recommendations 5 have given the stock a Buy while 8 recommend the stock as Outperform. 7 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Incyte Corporation (NASDAQ:INCY)’s shares climbed 10.37% in the past week and soared 14.83% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 6.89% while its year to date performance is at 18.13%.

While taking a glance at financials, we can look at a number of key indicators. Incyte Corporation (NASDAQ:INCY) has a Return on Assets (ROA) of -4.6. The company currently has a Return on Equity (ROE) of -6.4 and a Return on Investment (ROI) of -14.8. Average true range (ATR-14) of the company sets at 3.08, along with its weekly and monthly volatility of 4.29% and 4.56% respectively. Relative strength index (RSI-14) for Incyte Corporation (NASDAQ:INCY) is at 68.81. Beta value of the stock stands at 1.08.

The company’s price to free cash flow for trailing twelve months is 178.26. Its quick ratio for most recent quarter is 4 along with current ratio for most recent quarter of 4. Total debt to equity ratio of Incyte Corporation (NASDAQ:INCY) for most recent quarter is 0.01 whereas long term debt to equity ratio for most recent quarter is 0.01.

Shares of Marinus Pharma CS (NASDAQ:MRNS) plunged -1.13% or -0.04 to reach at $3.51 during previous trading session. Marinus Pharma CS (NASDAQ:MRNS) has a market capitalization of $171.92 Million and most recently 48.98 Million outstanding shares have been calculated. A total of 434396 shares exchanged hands, whereas the company’s average trading volume stands at 1.32 Million shares.

According to 6 analysts Marinus Pharma CS (NASDAQ:MRNS)’s price will reach at $20.33 during 52 weeks. Stock’s minimum price target estimates has been figured out at $13 while the maximum price target forecast is established at $29.

According to the recommendations from 4 analysts stock has mean rating of 1 on the shares of Marinus Pharma CS (NASDAQ:MRNS). Out of rating recommendations 2 have given the stock a Buy while 4 recommend the stock as Outperform. 0 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Shares of Marinus Pharma CS (NASDAQ:MRNS) climbed 12.86% in the past week and plunged -33.02% in the last 4 weeks, historically the stock illustrate that its six months performance stands at -56.02% while its year to date performance is at 22.3%.

Total debt to equity ratio of Marinus Pharma CS (NASDAQ:MRNS) for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0. The company’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 5.9 along with current ratio for most recent quarter of 5.9.

Average true range (ATR-14) of the company sets at 0.44, along with its weekly and monthly volatility of 9.23% and 12.55% respectively. Relative strength index (RSI-14) for Marinus Pharma CS (NASDAQ:MRNS) is at 47.15. Beta value of the stock stands at 3.32. Marinus Pharma CS (NASDAQ:MRNS) has a Return on Assets (ROA) of -60.7. The company currently has a Return on Equity (ROE) of -65.6 and a Return on Investment (ROI) of 0.